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Modified, non-neurovirulent herpes siInplex viruses 
(HSV) have shown promise for the treatment of brain 
tlnYlol"s, including intracranial melanoma. In this 
report, we show that HSV-1716, an HSV-1 mutant 
lacking both copies of the gene coding-infected cell 
prot:ein 34.5 (ICP 34.5), can effectively treat experi-
ment:al subcutaneous human n1.elanoma in mice. III 
vitro, HSV -1716 replicated in all 26 human melanoma 
cell lines tested, efficiently lysing the cells. Thel"apeu-
tic infection of subcutaneous human Inela.noma nod-
T he incidence of melanom. a has been iJ1creasing worldwide fo r the last 20 y (Balch el nl, 1983). The Cell tel's for Djsease Control recently reported that the incidence of melanoma in the United States iJ1creased about 4'10 per ycar between 1973 and 1991 
with a concomitant 34°1., ri se in death rate (Anonymous, 1995) . At 
present, advanced (stage 4) melanoma is refi'actory to a.ll standard 
cancer therapies Oohnson el ai, 1995) . 
Viral-based treatment of tumors has been reported in experimen-
tal systcms with parvovirus 1-1-1 , N ewcastle disease virus, retrovi ral 
vectors containing drug susceptibi li ty ge lles, and herpes simplex 
type I vinls (HSV-l) (DLlpl'essoir el nl, 1989; Martuza et ai, 1991; 
Markert et ai, 1992; R eichard eI ai, 1992; Ram cl ai, 1993; Takamiya 
e/ a i , 1993). T he mechanisms by which viruses improve tlle 
outconle in experimental tumor systems are complex and incom-
pletely understood. As is the case for host ce lls during a natural 
infection, tumor cells infected during a therapeutic viral infection 
call be damaged or killed directly by the virus or by immune 
responses to the virus. 
Published uses of modified , replicating HSV to treat cancer have 
cen tered around tumors of central nervous system origin (Martuza 
et a i , 1991; Markert eI nl, 1993 ; Boviatsis et ai, 1994; Jia el ai, 1994; 
Mll1eta el ai, 1994; Randazzo el ai, 1995). I-ISV-1716 is a mutant 
that has a 759-bp deletion in the genes coding for infected cell 
protein 34.5 (ICP 34.5) (MacLean el ai, 1991). This mutation, 
through mechanisms that are unclear, se verely attenuates the ability 
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ules with HSV -1716 led to viral replication that was 
restricted to tumor cells by immunohistochemistry. 
Moreover, HSV - 1716 treatment significantly inhib-
ite d progression of prefol"med subcutaneous human 
melanoma nodules in SCID mice and caused com-
plete regression of some tumors. This work expands 
the potential scope of HSV -1-based cancer therapy. 
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of I-1SV-1716 to rep licate ill nOl'mal tissues (MacLeaJ1 l!1 nl, 1991; 
Robertson el nl, 1992; Spivack el nl, 1995) but does not appear to 
affect the virus' ability to replicate in malignant cells (Randazzo et 
nl, 1995 ; Mckie et ai , 1996; Kucharczuk et ai, 1997). T he virulence 
of I-I S V -1716 is extremel), attenuated in an imal models of HSV 
pathogenesis (Valyi-Nagy Ci aI, 1994; Spivack el nl, 1995). More-
over, we have shown that I-ISV -1716 replicates poorly in normal 
human skin grafted onto severe combined immunodeficient 
(SCI D) mice and have used this virus to successfully treat intracra-
nial tllmors, including melanoma, and intraperitoneal human me-
sothelioma, in nonnal and i.mmunodeficient mouse mode)s (Kesari 
el ai, 1995; Randazzo el ai, 1995 , 1996; Kucharczuk el ai , 1997). 
Beca use of (i) the lack of effective therapy for advanced m ela-
noma. (ii) our success treating melanoma brain tumors, and (ui) the 
attenuated replication ofHSV-1716 seen in normal ti ssues , we have 
ini tiated experim en ts to srud)' HSV-1716-based t.herapy of subcu-
taneous human melalJoma. 
MATER.IALS AND METHODS 
Tumor Cells HumaJl melanoma cell lines (a generous gift from Mcen-
hard Hcrlyn, Wistar Institute, Philadelphia, PAl were isolated as previously 
reported (Juhas~ er ai, 1993). Lines 1205 and WM-451-Lu were derived 
from I11ctastatic tUI110 r nodules. Ccll ~ werc: grown in plastic Aasks in 
AUTO-POW m edia containing penicillin, streptomycin. and 5% calf serum 
at 37°C in a hu midified environment with 5% COo. 
Virus Production To produce virus stocks. subcortAuent monolayers of 
baby ham ster kidney 21 clone 13 (BHK) cells were infected with HSV 
stra ins .I 716 or wild type 17 " . Virus was concent.rated 6:0 111 the culture and 
titrated by plaque assay (Spivack and Fraser. 1987). All viral stocks are 
sto red froze n at - 70°C and thawed rapidly just prior to use. 
Production ofUV-Inactivated V irus U ltra violet inactivation ofH5V 
was performed using the method of Notarianni and Presto n (1982). After 
inactivation, the viral suspension was titered on BI-IK ce ll s to confirm that 
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it cou ld no longer establ ish" lytic in fec tion . stored frozen at - 7{)OC, Hnd 
th"wed rapidl y just prio r to usc. 
Vira l Growth Kin e ti c s Assay Subconfluent mono layers (5 X 10' cells 
in six-we ll p lastic tissue cul ture plates) were in fected with 5 X '10' 
plaq ue-form ing units (PFU) of H SV ill 'I ml of AUTO-POW "H:dia 
contain ing pe n.icillin , and st reptom yc in . For the time 0 measurement. the 
cell monolayer was scr<lpcd off immediately in to tbe viral inoculum 
suspension and f1:ozcn at - 70°C. For the n~ll1 a lJ1 iJ1 g tirnc p OiJltS. the viral 
inoculum was in cubated on the ce ll mOllo laye r at 37°C for 1 h with gentle 
rocking and thell asp irated o ff. T he in fected monolaye rs were washed twice 
with media and resuspcll ded in 1 1111 of AUTO-POW Illedia con t;l ining 
penici ll iJl, streptom ycin , and 5% ca lf se rum . At the appro priate rimes post 
in fectio n, the monolayers were harvested with a ce ll scraper. ,l\ld the 
suspension "';I S frozen at - 70°C. Follo wing twO cycles o f freez ing and 
thawing. e"ch sampl e was ritrated by plaq ue assay on BHK cells (Spivack 
and Fras<.:r, 1987). 
CeU Viability Assay Cells were plated in 96 wdl plates at a d<.:nsity of 
5 X 10,1 ce lls pe r well. Twenty four hours later the ce ll s we re inr",cted with 
HSV- I 716 at a multiplicity of infecri on (M O l; the ratio of plaque fo rming 
uni ts of vin,lS to c<.: lIs) of 0 , 0 .01 , 0 .1 , o r 1.0, o r HSV - 17+ a t an MO l oro .·1 . 
Viabil ity was assessed at 24, 48, 72 , and 96 h post infection (CellTiter 96 
Aq ueous Nonradioacti ve MTT Cell Proliferation A,lsay; Prom ega Corpo-
ration, Madison WI) . T he percent viability is defin ed as the ra tio of the 
Illean absorbance of six treated we lls at 490 11111 to the m <.:a n absorbance of 
six unjn fected con tro ls at each time point . Background absorbance, o b-
ta in ed by lysing LlniJlf<.:c ted cells w ith TI~ton X l 00 at a final concentration 
of 10'X, was sub tracted from all experimen ta l valu C!s prior to ca lculations. 
Subc utan e ons Tnmor Produc tion and Assays M ice were anesthe-
tized w ith in tramuscular ketamine/xylazinc (87 mg ketall1ine/kg; 13 rng 
xylazine/kg). A patch of hair was rellloved from Olle fl ank using a chemic;,) 
depilatory agen t (Magic Sh;.ving Powder. Carson Products Co .. Savannah 
GA.) Subcutaneous injection of L X 105 of e ith<.:t 1205 Or W M-4 51-Lu 
melanoma cell s in a tota l vo lume of 50 ",I was perfo rmed using a H amilton 
syringe and a d isposable 28 g ncedle. T umor volumes as.<ume a spheri cal 
tumor shape, and we re c<l lculated based on a rad ius obtained from 
orthogonal I11CaSUrCfn el1 [S o f [Ulno r d ianlctcrs using a ll,iCr0 I11 cter-ca lipcr. 
For the cXpCrilTlCT1 ts w ith 1205 J1H.: la n 0 I11a, I11ice w"ere randol111 y divided in to 
three g.-oups on day 14 post tumor cell injec ri on. O ne group was rre<lted 
with a 25 ",I intra tumor,,) injection 0[2.5 X 10(' PFU ofH SV-l 716 using a 
H amilto n syringe and a disposable 30 g needle. The second and third gro ups 
werc injected , respccri vcly, with (In equal volume of UV-iJlacti vatcd 
HSV- 1716 or viral cu lture medium alone. For the experiments with 
WM-451-Lu mel,moma, mice were randomly d ivided in to two gro ups on 
day ' 28 post tumor cell injection . O ne gro up was treated with a 25 ",I 
intra tumoral injection of2 .5 X '10" PFU of H SV -171 6. and the o ther group 
was injected wi th an equal vo lume of UV- inactivated HSV-1 716. 
Immunohistochemistry Viral an tigen-expressing cell s were detected 
by the indirect avidin-bio tin illlmuno peroxidase method (Vecto r Labs, 
B uriingn m, CAl as specified by the manufacturer w ith slight modi fications 
developed in our laboratory (Gessel' el ai, 1994). R abbit anti se rum to H SV-1 
(Dako Corp., Carpinteri a, CA l was used at a dilu tion o f 1:1000. 
Statistical Analysis Data analysis, incl ud ing calculations of means, 
standard deviations. and repeated measures analysis of v"rian cc (A NO VA), 
w as pcrfonned using StatView statistica l software (Abacus Concepts. 
Berke ley CA) on an Apple Mac intosh computer (Cupertino, C A) . 
RESULTS 
As an initia l step in assess in g the viabili ty of H SV-based the rapy of 
human m elan o ma , th e e ffi cien cy o f HSV -171 6 replkation was 
d etermin ed fo r a pan e l o f human m e lanoma ce ll lines and compare d 
to th e replj ca tio n o f H S V-1 7 + , the pare nta l stnlin from which 
H S V-1716 w as d e ri ved. A re presentative expe rime nt utiliz ing th e 
1205 melan o ma cell linc is shown in Fig 1. The kiJletics of vinl s 
pro du ction were n earl y ide ntical fo r H SV-1 71 6 and H S V-17 + . T he 
replicatio n cycle o f HSV-171 6 in th ese cell s is approximately 24 h, 
and each re p lica tion cycle yields an appro ximately 4 log fo ld 
in c rease in Iy tic all y ac ti ve v iru s. 
To d e monstrate th e abili ty o f H S V-171 6 to directl y kill human 
m elanoma cell s, w e p e rfo rme d ill vitro cell vi abili ty assays at vario u s 
times fo llo win g v iral infection. A re presenta tive exp e rime nt utili z-
in g th e 1205 melan o m a cell line is shown in Fig 2 . A t MOls 
ran gin g fro m 0.0 1-1.0, HSV-1716 e ffi c ie ntly kill e d the tumor cells 
in a t im e- and dose-resp o n sive fa shion . 
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Figure 1. HSV - 1716 and HSV-17 + replicate efficiently ill human 
n1Clal1oma c ells ill l'i/l'O. SubconAlIent monol<l ye rs o f 12{) 5 cells were 
infected wi th 5 X 10J PFU or I-ISV -1 716 o r H SV 17+ For the rillle 0 
measurem en t:, tbe cell monolaye r was scraped o fF into the viral inoculum 
suspension immediately and frozen . For the remaining time POillts, the viral 
inocululll was incubated on the ce ll mono layer at 37°C fo r 1 h with gentle 
rocking and thell aspir"ted off. The infected mono l,, ),ers Were washed twice 
with media and resuspended in l ml of AUT O-PO W media containing 
pe n.i cillin , streptom ycin, and 5% calf serum . At the <l ppropriate times post 
in fec tion, the monolaye rs were harvested wi th a cdl scraper. and the 
suspension was fi'ozcn at - 70°C. Following two cycles of fi'cezing and 
thawing, each sample was tio'ated by plaque assay on nHK cells. T he data 
shown represent the mean :!: SD o f tripli cate de tenninations at each time 
poillt. 
A total o f26 human m elanoma cell lines were teste d similarly fo r 
ly ti c replica tio n of HSV , and all o f these r eplicated HSV -1716 and 
HSV-17 + e ffi c ie ntly ;'1 lI ill'O (da ta not shown). 
W e n ext d e te rmin ed whe the r replication of HSV -1716 cou ld be 
demonstrated ill Vill O in pre -forme d subc utan eous human melanoma 
nodules g r owing Ul SClD mouse skin and , m o re importantly, 
e valu a te d whe the r re plica tion o f the virus was d e tectable in 
surrounding normal ti ssues . Tlus was accomplished b y immullohis-
tochenLi cal evaluation of treated tumors and surrounding tissue s. As 
shown i.n re presenta tive sections in Fig 3 , immullobistoche micaJ 
s taining o f subc u tan e ous 12 05 m e lanom a nodul es with antibody to 
HSV at 5 d (Fig 3B,Q or 10 d (Fig 3D,E) afte r intra tUlTIoral 
injec tion of HSV-1716 d e m o n strates positive sta i.niJl g that is dis-
pe rsed thro u g hout a large are a of the tumor. At these times a 
s ignifica nt portion of tll e HSV-171 6 -treated rumor nodules are 
n ecro tic. Moreover, no staining is obser ved in n o rmal murine 
ti ssu es surrounding the tumor nodules in these and aU oth er 
sections e x amined. No stai.ung, and n o sig nificant n ecrosis o c-
c urre d in the re pre sentativ e control t umor tre ate d w ith UV-
inactivated HSV-171 6 and subjected to th e fuJJ immuno hjstoch em-
ica l protocol (Fig 3A) . 
FUlally, to d e finitively test the ill l)iJ)O effic acy of tlus approach , w e 
attempte d the rapy of pre-formed subc utaneous tumors. A s shown 
in Fig 4A, HSV-1716 sig nifi cantly inhibits progression of pre-
form e d subc utan e ous 12 05 melanoma tumor nodules re la ti ve to 
control tulllors tre ate d with UV-illac tiv ate d virus (p < 0 .0001 ; 
re p eate d m e asures ANOV A) and also re la tive to control tumors 
trea te d with c ulture m e dium alone (p < 0.0001 ; repeated measures 
ANOVA). In addition, it was found that UV- inactivated HSV-171 6 
had no e ffec t on tumor progressi o n re lati ve to tumor nodules 
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injected with viral culture medium alon e (p = 0.8238; repeated 
measures ANOVA). Of the ten mice bearing 1205 melanoma 
tumOTS treated with HSV -1 7 16 in this representativ e cxperimcnt, 
three had complete involution of melanoma nodules su ch that no 
palpable tumors were present £i'om day 21 on. As shown in Fig 4B, 
HSV-1716 sign.ifi cantly inhibits progression of pre-formed subcu-
tan eous WM-451-Lu melanoma tumor nodules relative to control 
tumors treated wi.th UV-inacti va ted virus (p = 0.0012; repeated 
measures ANOVA), For HSV-1716-o'eated mice beal'ing WM-
451-Lu melanoma, four of ten had compl ete regression of subcu-
taneous nodules by day 42. In tllese mice, regression was subse-
quently confirmed histologicall y (data no t shown) . In none of the 
HSV-1716 -treated animals ... vas there any mortali ty or morbidity 
note d . 
D ISCUSSION 
In this report we demonstrate that the " replication- restricted" 
herpes simpl ex mutant HSV -171 6 is a safe and effective therapy for 
pre - formed subcutaneo us human melanoma nodules in SClD mice. 
TIle virus used for o ur studies, called HSV-1716, has a 759-bp 
deletion in tll e ICP34.5 gene (MacLean el nl, 1991). 111 "il l'll, 
lCP34.5 null HSV-1 mutants grow as well as wild-type virus on 
cells of m ost established ceB lines (Chou et aI , 1990; MacLean ct til , 
1991 ; Bolovan el til, 1994) . On primary cells, however, these 
viruses show impaired repJjc~tion (Bolovan el til, 1994) . III V;I)O, 
ICP34.5 nuLl HSV-l mutants are relatively avir ulent. T hey repli-
cate margin ally if at all within the central nervous systcm of 
immunocompetent mice and do not cause encephalitis (Chou ct nl, 
1990; Ta ha e( til, 1990; MacLean el (/1 , 1991), in sharp conO'ast to 
w ild-type HSVs, which grow exponentiall y in br;lin and kill mice 
within days of inocu lation (MacLean et nl, 1991). T hese mutants 
also show impaircd or no repJjca rion in non-neuronal tissues of 
exp erimental animals, such as com eal epithelium and vaginal 
LUueOS,1 (Whitley cl til , 1993; Spivack cl ai, 1995). We have shown 
that relativ e to wild-type HSV-17 + and the revertant virus HSV-
1716R, the rep lication ofHSV -1716 is severely restricted in normal 
hun')an skin xenografts growing on SCID mice (Randazzo el til, 
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F igurc 2. HSV-l716 cfficicntly kills human 111clanoma cclls ill "ill'O. 
Cells were plated ill 96-well plates at a dellsity of 5 X 10.1 cells per well. 
Twenry four hours la ter the cell s were infec ted w ith HSV-1716 at all M O L 
of 0, 0 .01, 0 .1, or 1.0, o r H SV-17 + at all MO L of 0.1. Viabiliry was assessed 
a t 24, 48, 72, and 96 h post infection (CdlTiter 96 Aqueous N onradioactive 
MTT Cell Prolifera tion Assay; Prom ega Corporation , Madison WI). Each 
data point is derived from the mean of six identica l wells. The percent 
vjabiliry is defined as : (absorbil/1 ce-iJ1fecred well s - background)/ (absor-
bance uninfected we lls - background) Background absorballce was ob-
tained by lysing uoillfected cells with Triton X l 00 at " fi nal concentration 
of lO'X,. 
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Figure 3 . Replication ofHSV-1716 is restricted to melanoma cells 
following inj ection into pec-formed subcutaneous tUinor nodules. 
Subcutaneous tumors were produced by irU"ction of 1 X 105 1205 
melanoma ce lls into SCIO mice. O n da)' 14 post tum or cell injection. some 
mice were treated with an ino'3 ttllllo ral injection of 2.5 X lO r. PFU of 
HSV-171 6, while control mice received an equi va lent vo lume of UV-
inactivated virus. F ig ure 3A sho\vs a representative se c tio n frolll a control 
[lll110r treated with UV - inactiva ted 1716 and harvested 10 d later. Figurc 
3B,C shows representative low and higher power sections frO I1\ a tumor 
treated with H SV - 17 16 and harvested 5 d later. F igure 3D,E shows 
representative low and higher po,vcr sections fn.)lll a tunlor treated with 
H SV-171 6 alld harvested 10 d later. T he rumor and surTounding skin were 
excised, tixed , sta ined imJ)Junohistochcmica lly for HSV-l. and COullC<!r-
stained w ith h ematoxylin . All sections arc oriented with th e cl'jdcrmj .~ 
overl ying the tlllllor nodule facing toward the rigllf side of the pane\. Scale 
bar, 1 mm (pa llcls A , B, 0); 250 J.l.111 (pt/ llds C, E) . 
1996). Mo reover, an extremely sensitive PCR based ~ssay failed ro 
detect dissemination of HSV-1 716 into any normal t issues fo llow-
ing intraperiton eal in fectio n of human mesothelioma-bearing 
SCID mice (Kucharczuk el ai , 1997). T hus, there is considerable 
data fro m rodents showing that lCP 34.5 null HSV poses little risk 
to the host. 
The new·otfopi c nature of HSV suggests that neural crest-
derived melanoma ce l.l s would be a good host cell for this virus . 
O ur expel;ence with murine melanoma , howc\rer, is that the 
m;0ority of tllese celJ lines ;Ire refi'acrory to HSV infectio n 
(Randazzo e/ (/1, 1995; and B.P. Randazzo, unpublished obser'va-
tion s). T his is ~pparently not an issue with hum~n m elanoma 
because we now report that an 26 lines examined, derived from 
primary and metastatic patient material, supported brisk lytic 
replication of HSV. 
Efficacious therapy of experimental m elanoma has been demon-
strated with suicide gene transfer using ill I'irl'O trnnsfection and ill 
villo adeno vira l mediated infection (Golumbek Cl ai, 1992; Vile and 
H art, 1993; Borll1ekoh ef nl, 1995). T hese approaches have uti lized 
the HSV thymidine kinase (HSV TK) gene to tl'anster susceptibili ty 
to ganciclovir to tumor cells. Although aden ovi ral based gene 
transfel' typically results in transduction of onl y 1-2% of tile tumor 
cell s within a nodule, a 40 - 50'Yc, reduction in tumor growth I'ate 
was ctFected (Bonnekoh CI nl, 1995) . Such reductions in tumor 
growth rate in the face of relative ly inefticien t gene transfe r is 
ascribed to a poorly understood " bystander effect." HSV-1 716 
contains the very HSV TK gen e utilized in tile gene transfer 
experiments noted above. As shown in Fig 3, the efficiency of 
HSV-171 6 spread through the experimental melanornas is vcry 
good and certainl y far exceeds the 1-2% tumor cell transdu ction 
reported for adenovirus-based tra nsduction following direct intra-
tumoral injection. O n e could en vision a the rapeulic approach in 
which efficient infection of a tun-\OI' would be accomplished with a 
repJjcation-res tricted mutant such as HSV-1716 and followed up 
with systemic ganciclovir. T hus, direct lytic infection and killing of 
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Figure 4. Intratumoral treatment of pre-formed subcutaneo us melanoma with HSV-1716 callses a significant inhibition of tUlllor 
progression. For the cxpcrimcnt shown in (AJ, ancsthctized l1Ii ce were injectcd subcutaneously with ·1 X ·1 U' ·1205 melanoma cc ll s. O n day 14 post tumor 
ce ll injection. mice were randomly divided in to three groups. O ne group was treated with a 25 /1-1 intratumom l injection of2 X 10" pFU of HSV- 1716, and 
animals in the two control groups were injected with either an equal vo lume of UV-inactivated 1716 or vira l cul ture medium. T he experiment presented 
is One of two pe rfonl1cd, .lnd both yie lded essen tia ll y idcntic:d resu lts. For the ex pe rim e ll t shown in (B), anesthetized mice were injected subcll taneoll sly with 
1 X 105 WM-45 1-Lu melanoma ce ll s. O n day 28 post tumor cell inj ection. mice were randomly divided into two groups. O ne group was treated with a 
25/1-1 intratullloral injection of2 X 10" PFU of HSV-1716, and allimals in the cOll trol group wen: injected with an eq ual vo lullle of UV-inactivated ITl6. 
T he data shown represent the Illean ± SI) or 10 mice at each poillt. 
tumo r cell s would bc augm c nted by a bystander effect to improve 
efl-icacy. 
A requ irement fo r inj ection of virus directly into tumor nodules 
is a potential limitation for t reatment of w idesp read m etas tati c or 
o ccult disease. which is p resently the most refi'actOl-y form of 
melanoma. It is possi ble. however. that vira l based tumor therapy 
cou ld in voke a therapeuti ca ll y be nefic ial vaccin e e ll"ect that cou ld 
.1L1 gm e n t the di rect lytic e ffects seen ill " ifm and in a SC IDI 
xenograft m odel system. It has been shown that infection of 
nonimmu nogenic tumor ce ll s w ith inAu en za virus, ecto tropic ret-
rovirus , o r h ybridization with a ll ogeneic partne r cell s can indu ce 
immuno logic rej ection responses aga in st the o rigina l unmodifi ed 
tumor cell s (Klein and Boon, ·1993). Alth ough the exact m echa-
nisms of this e ffect arc un clear. i t is li ke ly that it is a result of 
improved antigen presenta tion and o r he lper ell"ects . We are 
presently in vestigati ng w hether l-)SY the rapy ca n induce a specific 
immune response directed aga in st noninfected tu m or ce lls. It is our 
ho pe that this w ill a llow for extensio n of efl-icacy to untreated and, 
possib ly. uninfected tumor ce ll s. broade nin g the app licabili ty o rthis 
approac h . 
T he re is clearly signifi cant work remaining be fo re the ultimate 
u ti li ty of HSY-based melanoma the rapy can be determined. We 
view this study as an impo rtant proof o f principle . w hich suggests 
the exciting p otential of thi s the rapeuti c approach . 
I,Ve nrc i"ddJfNI IO D r. G. RO/ll'm./()/' Itis COII/illl/ I'd i/Hcrcs l ;11 ,ltis IIIv rk. T his work 
11' 11 .1 slIl'l'tlrl ed ill 1''' 1'1 hy II J!lf rsl lI',,<)d-Sqllihh P/IflI'III nn·lllicn/s Cnrea O<'/I"'OjJlII<"1I1 
A llinI'll, (I IIItln /cd 'h rough the Derlll a/%gy FO lflu/nliol1 , T'ft e Jl II)(TI '['(I .Y;" Nlt:lIl orinl 
F llml , Gmllt IR G- '135PjJ'() JII thl' A mcrica/l C tllltl'r Society . tt lld f\'mi(lltttllllstillltf 'S 
(~r Henl/" C rn ll l I K08CA65839. 
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